Cargando…

The Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial

BACKGROUND: Postoperative bleeding after cardiac reoperations is among the most complicating problems, both for the physicians and for the patients. Many modalities have been used to decrease its adverse effects and the need for blood products administration. OBJECTIVES: In a randomized double-blind...

Descripción completa

Detalles Bibliográficos
Autores principales: Payani, Narges, Foroughi, Mahnoosh, Dabbagh, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350162/
https://www.ncbi.nlm.nih.gov/pubmed/25789239
http://dx.doi.org/10.5812/aapm.22846
_version_ 1782360146906710016
author Payani, Narges
Foroughi, Mahnoosh
Dabbagh, Ali
author_facet Payani, Narges
Foroughi, Mahnoosh
Dabbagh, Ali
author_sort Payani, Narges
collection PubMed
description BACKGROUND: Postoperative bleeding after cardiac reoperations is among the most complicating problems, both for the physicians and for the patients. Many modalities have been used to decrease its adverse effects and the need for blood products administration. OBJECTIVES: In a randomized double-blinded clinical trial of redo cardiac valve surgery in adult, the effect of active recombinant factor VII (rFVIIa) on postoperative bleeding was compared with placebo. Chest tube drainage was used for comparison of bleeding between the two groups. PATIENTS AND METHODS: Two groups of 18 patients undergoing redo valve surgeries were treated and compared regarding chest tube drainage, need for blood products, prothrombin time (PT), partial thromboplastin time (PTT), hemoglobin and hematocrit, platelet count, and international normalized ratio (INR) in first 24 hours after surgery. Bleeding was assessed at 3rd, 12th, and 24th hour after operation. In rFVIIa group, 40 µg/kg of AryoSeven was administered before end of surgery and same volume of normal saline was administered as placebo in the control group. RESULTS: Study groups showed no difference regarding baseline variables. Three patients in rFVIIa group (16.67%) and 13 in placebo group (72.23%) received blood products (P < 0.01). Chest tube blood drainage at 24th hour after operation was 315 ± 177 mL in rFVIIa group and 557 ± 168 mL in control group (P = 0.03). At third and 12th hour after operation, the difference was not statistically significant (P = 0.71 and P = 0.22, respectively). Postoperative ICU stay was not different; while extubation was longer in the placebo group (352 ± 57 vs. 287 ± 46 minutes; P = 0.003). CONCLUSIONS: Our study demonstrated the efficacy of rFVIIa in controlling postoperative bleeding in redo cardiac valve surgeries regarding subsequent blood loss and transfusion requirement; however, outcome results remains to be defined.
format Online
Article
Text
id pubmed-4350162
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-43501622015-03-18 The Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial Payani, Narges Foroughi, Mahnoosh Dabbagh, Ali Anesth Pain Med Research Article BACKGROUND: Postoperative bleeding after cardiac reoperations is among the most complicating problems, both for the physicians and for the patients. Many modalities have been used to decrease its adverse effects and the need for blood products administration. OBJECTIVES: In a randomized double-blinded clinical trial of redo cardiac valve surgery in adult, the effect of active recombinant factor VII (rFVIIa) on postoperative bleeding was compared with placebo. Chest tube drainage was used for comparison of bleeding between the two groups. PATIENTS AND METHODS: Two groups of 18 patients undergoing redo valve surgeries were treated and compared regarding chest tube drainage, need for blood products, prothrombin time (PT), partial thromboplastin time (PTT), hemoglobin and hematocrit, platelet count, and international normalized ratio (INR) in first 24 hours after surgery. Bleeding was assessed at 3rd, 12th, and 24th hour after operation. In rFVIIa group, 40 µg/kg of AryoSeven was administered before end of surgery and same volume of normal saline was administered as placebo in the control group. RESULTS: Study groups showed no difference regarding baseline variables. Three patients in rFVIIa group (16.67%) and 13 in placebo group (72.23%) received blood products (P < 0.01). Chest tube blood drainage at 24th hour after operation was 315 ± 177 mL in rFVIIa group and 557 ± 168 mL in control group (P = 0.03). At third and 12th hour after operation, the difference was not statistically significant (P = 0.71 and P = 0.22, respectively). Postoperative ICU stay was not different; while extubation was longer in the placebo group (352 ± 57 vs. 287 ± 46 minutes; P = 0.003). CONCLUSIONS: Our study demonstrated the efficacy of rFVIIa in controlling postoperative bleeding in redo cardiac valve surgeries regarding subsequent blood loss and transfusion requirement; however, outcome results remains to be defined. Kowsar 2015-02-01 /pmc/articles/PMC4350162/ /pubmed/25789239 http://dx.doi.org/10.5812/aapm.22846 Text en Copyright © 2015, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM). http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Research Article
Payani, Narges
Foroughi, Mahnoosh
Dabbagh, Ali
The Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial
title The Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial
title_full The Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial
title_fullStr The Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial
title_full_unstemmed The Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial
title_short The Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial
title_sort effect of intravenous administration of active recombinant factor vii on postoperative bleeding in cardiac valve reoperations; a randomized clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350162/
https://www.ncbi.nlm.nih.gov/pubmed/25789239
http://dx.doi.org/10.5812/aapm.22846
work_keys_str_mv AT payaninarges theeffectofintravenousadministrationofactiverecombinantfactorviionpostoperativebleedingincardiacvalvereoperationsarandomizedclinicaltrial
AT foroughimahnoosh theeffectofintravenousadministrationofactiverecombinantfactorviionpostoperativebleedingincardiacvalvereoperationsarandomizedclinicaltrial
AT dabbaghali theeffectofintravenousadministrationofactiverecombinantfactorviionpostoperativebleedingincardiacvalvereoperationsarandomizedclinicaltrial
AT payaninarges effectofintravenousadministrationofactiverecombinantfactorviionpostoperativebleedingincardiacvalvereoperationsarandomizedclinicaltrial
AT foroughimahnoosh effectofintravenousadministrationofactiverecombinantfactorviionpostoperativebleedingincardiacvalvereoperationsarandomizedclinicaltrial
AT dabbaghali effectofintravenousadministrationofactiverecombinantfactorviionpostoperativebleedingincardiacvalvereoperationsarandomizedclinicaltrial